GlassScriptPhysician profile
Darla B Hobbs
NPI 1821244302
$7,320.11
in general payments reported to CMS, 2019-2025
26 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,400 · 2022: $1,783 · 2023: $1,466 · 2024: $1,470 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,858 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,858.05 |
| Education | $278.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,383.10 | 2021-2025 | |
| Genzyme Corporation | $820.42 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $792.10 | 2021-2025 | Blu-U, Ilumya, Winlevi |
| Janssen Biotech, INC. | $715.75 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $630.36 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $431.49 | 2021-2025 | |
| Ucb, INC. | $391.60 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $353.58 | 2021-2025 | Dupixent |
| Amgen INC. | $287.18 | 2021-2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $279.74 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $189.84 | 2021-2025 | Adbry |
| Lilly USA, LLC | $170.85 | 2021-2024 | Ebglyss, Taltz |
| Incyte Corporation | $160.27 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $119.57 | 2021-2025 | Dysport, Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.96 | 2023-2024 | Spevigo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $116.48 | 2022 | |
| Arcutis Biotherapeutics, INC. | $80.11 | 2023-2025 | Zoryve |
| Biofrontera INC. | $67.90 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Merz North America, INC. | $49.60 | 2024 | |
| Almirall LLC | $49.37 | 2023-2025 | Seysara |
| Genentech USA, INC. | $35.01 | 2024 | Xolair |
| Kyowa Kirin, INC. | $21.93 | 2025 | |
| Mallinckrodt Hospital Products INC. | $19.24 | 2024 | Acthar |
| Epi Health, LLC | $17.50 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $15.59 | 2025 | Valchlor |
| Organon LLC | $3.57 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darla Hobbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.